Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Article Details
- CitationCopy to clipboard
Uy GL, Rettig MP, Cashen AF
Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. doi: 10.1517/14712598.8.11.1797 .
- PubMed ID
- 18847313 [ View in PubMed]
- Abstract
Stem cells harvested from peripheral blood are the most commonly used graft source in hematopoietic stem cell transplantation. While G-CSF is the most frequently used agent for stem cell mobilization, the use of G-CSF alone results in suboptimal stem cell yields in a significant proportion of patients undergoing autologous transplantation. Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4. Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF. In clinical studies of autologous stem cell transplantation, the combination of plerixafor and G-CSF allows the collection of large numbers of stem cells in fewer apheresis sessions and can salvage those who fail G-CSF mobilization alone.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Plerixafor C-X-C chemokine receptor type 4 Protein Humans YesAntagonistInhibitorDetails